<DOC>
	<DOCNO>NCT01213355</DOCNO>
	<brief_summary>It hypothesize PF-05212377 ( SAM-760 ) reverse scopolamine induce cognitive impairment healthy adult subject .</brief_summary>
	<brief_title>Scopolamine Challenge Study</brief_title>
	<detailed_description>Proof mechanism</detailed_description>
	<mesh_term>Donepezil</mesh_term>
	<mesh_term>Scopolamine Hydrobromide</mesh_term>
	<mesh_term>Butylscopolammonium Bromide</mesh_term>
	<criteria>Healthy male and/or female subject non child bear potential ( WONCBP ) age 18 55 year , inclusive . Body Mass index ( BMI ) 17.5 30.5 kg/m2 inclusive ; total body weight great equal 50 kg ( 110 lb ) . Presence history disorder may prevent successful completion study . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Randomized</keyword>
	<keyword>double-blind</keyword>
	<keyword>placebo-controlled</keyword>
	<keyword>5-way crossover</keyword>
	<keyword>single oral administration PF 05212377</keyword>
	<keyword>scopolamine induce deficit healthy subject</keyword>
</DOC>